bpc-157 and tb-500 side effects FDA Panel Recommends Compounding Unapproved Peptides BIG peptide news: the PCAC

A B12 level above 300 pg/mL is considered normal

The evidence is preclinical mouse and cell studies

because rigorously controlled human safety data specific to the TB-500 fragment does not exist, its longer-term risk profile, including possible immune reactions, remains unknown Evidence snapshot: Evidence for TB-500 itself is preclinical, drawn mainly from cell-culture and animal studies (a 1999 rat wound-healing study and later rodent cardiac- and tendon-injury models), with a 2026 scoping review describing the musculoskeletal literature on thymosin beta-4 and TB-500 as sparse and largely preclinical

A consultation with our nurse practitioners helps identify whether your health history calls for any adjustments before you begin